Timurkaynak F, Arslan H, Azap O Kurt, Senger S Serin, Başaran O, Karaman S Ozbalikci, Haberal M
Başkent University, Faculty of Medicine, Department of Clinical Microbiology and Infectious Disease, Ankara, Turkey.
Burns. 2008 Nov;34(7):1033-6. doi: 10.1016/j.burns.2008.03.005. Epub 2008 Jun 9.
Infections in burn patients are usually caused by multidrug-resistant micro-organisms. Tigecycline, a derivative of glycylcyclines, is an effective antibiotic against the resistant strains. The aim of this study is to determine the in vitro activity of tigecycline against the multidrug-resistant bacteria isolated from burn patients. Fourty-seven bacteria isolated from 118 patients hospitalized in the burn unit during 2003-2006 were included in the study. Gram-negative bacteria that were resistant to at least six broad-spectrum antibiotics, methicillin-resistant staphylococci and ampicillin-resistant enterococci were studied. Minimal inhibitory concentration values of tigecycline against these bacteria were tested by E-test strips. Susceptibility breakpoints were determined according to the previous studies; <or=0.25mg/L for enterococci, <or=0.5mg/L for staphylococci and <or=2mg/L for Acinetobacter baumannii. Thirty-six percent of the materials were obtained from tissue specimens, 30% from wound, 25% from blood and 9% from other samples (e.g., catheter, tracheal aspiration, urine). MIC(90) values were 2, 0.25 and 1.5mg/L and susceptibility rates were 99.4%, 93.6%, 85.5% for A. baumannii, enterococci and MRSA, respectively. To conclude, this study demonstrated that tigecycline exhibits in vitro activity against clinical isolates of MDR A. baumannii, MRSA, and Enterococcus spp. isolated from burn patients. Tigecycline is a promising therapeutic option for difficult to treat burn infections due to these pathogens.
烧伤患者的感染通常由多重耐药微生物引起。替加环素是甘氨酰环素的衍生物，是一种针对耐药菌株有效的抗生素。本研究的目的是确定替加环素对从烧伤患者中分离出的多重耐药细菌的体外活性。本研究纳入了2003年至2006年期间在烧伤科住院的118例患者中分离出的47株细菌。研究了对至少六种广谱抗生素耐药的革兰氏阴性菌、耐甲氧西林葡萄球菌和耐氨苄西林肠球菌。通过E-test试纸条检测替加环素对这些细菌的最低抑菌浓度值。根据先前的研究确定药敏断点；肠球菌为≤0.25mg/L，葡萄球菌为≤0.5mg/L，鲍曼不动杆菌为≤2mg/L。36%的样本来自组织标本，30%来自伤口，25%来自血液，9%来自其他样本（如导管、气管吸出物、尿液）。鲍曼不动杆菌、肠球菌和耐甲氧西林金黄色葡萄球菌的MIC(90)值分别为2、0.25和1.5mg/L，药敏率分别为99.4%、93.6%、85.5%。总之，本研究表明替加环素对从烧伤患者中分离出的多重耐药鲍曼不动杆菌、耐甲氧西林金黄色葡萄球菌和肠球菌临床分离株具有体外活性。由于这些病原体，替加环素是治疗难治性烧伤感染的一种有前景的治疗选择。
